c-Met inhibitor - Wikipedia
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer | Clinical Cancer Research
c-Met inhibitor - Wikipedia
MET inhibition in lung cancer - Menis - Translational Lung Cancer Research
Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
MET Inhibitors in NSCLC: Treatment Selection
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
Active or Recent Clinical Trials of hepatocyte growth factor (HGF)-MET... | Download Table
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
MET inhibitors in combination with other therapies in non-small cell lung cancer - Padda - Translational Lung Cancer Research
Inhibition of c-Met in NSCLC. A, inhibition of c-Met protein expression... | Download Scientific Diagram
Current Modalities in the Treatment of Lung Cancer
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer | Novartis
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Profile of c-Met Inhibitors in Clinical or Late Pre-Clinical Development | Download Table
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
